Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 89.76 USD 1.27% Market Closed
Market Cap: 111.8B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Intrinsic Value

The intrinsic value of one GILD stock under the Base Case scenario is 89.71 USD. Compared to the current market price of 89.76 USD, Gilead Sciences Inc is Fairly Valued.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GILD Intrinsic Value
89.71 USD
Fairly Valued
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gilead Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GILD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GILD?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Gilead Sciences Inc

Provide an overview of the primary business activities
of Gilead Sciences Inc.

What unique competitive advantages
does Gilead Sciences Inc hold over its rivals?

What risks and challenges
does Gilead Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Gilead Sciences Inc recently?

Summarize the latest earnings call
of Gilead Sciences Inc.

What significant events have occurred
in Gilead Sciences Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gilead Sciences Inc.

Provide P/S
for Gilead Sciences Inc.

Provide P/E
for Gilead Sciences Inc.

Provide P/OCF
for Gilead Sciences Inc.

Provide P/FCFE
for Gilead Sciences Inc.

Provide P/B
for Gilead Sciences Inc.

Provide EV/S
for Gilead Sciences Inc.

Provide EV/GP
for Gilead Sciences Inc.

Provide EV/EBITDA
for Gilead Sciences Inc.

Provide EV/EBIT
for Gilead Sciences Inc.

Provide EV/OCF
for Gilead Sciences Inc.

Provide EV/FCFF
for Gilead Sciences Inc.

Provide EV/IC
for Gilead Sciences Inc.

Show me price targets
for Gilead Sciences Inc made by professional analysts.

What are the Revenue projections
for Gilead Sciences Inc?

How accurate were the past Revenue estimates
for Gilead Sciences Inc?

What are the Net Income projections
for Gilead Sciences Inc?

How accurate were the past Net Income estimates
for Gilead Sciences Inc?

What are the EPS projections
for Gilead Sciences Inc?

How accurate were the past EPS estimates
for Gilead Sciences Inc?

What are the EBIT projections
for Gilead Sciences Inc?

How accurate were the past EBIT estimates
for Gilead Sciences Inc?

Compare the revenue forecasts
for Gilead Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gilead Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gilead Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gilead Sciences Inc compared to its peers.

Compare the P/E ratios
of Gilead Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Gilead Sciences Inc with its peers.

Analyze the financial leverage
of Gilead Sciences Inc compared to its main competitors.

Show all profitability ratios
for Gilead Sciences Inc.

Provide ROE
for Gilead Sciences Inc.

Provide ROA
for Gilead Sciences Inc.

Provide ROIC
for Gilead Sciences Inc.

Provide ROCE
for Gilead Sciences Inc.

Provide Gross Margin
for Gilead Sciences Inc.

Provide Operating Margin
for Gilead Sciences Inc.

Provide Net Margin
for Gilead Sciences Inc.

Provide FCF Margin
for Gilead Sciences Inc.

Show all solvency ratios
for Gilead Sciences Inc.

Provide D/E Ratio
for Gilead Sciences Inc.

Provide D/A Ratio
for Gilead Sciences Inc.

Provide Interest Coverage Ratio
for Gilead Sciences Inc.

Provide Altman Z-Score Ratio
for Gilead Sciences Inc.

Provide Quick Ratio
for Gilead Sciences Inc.

Provide Current Ratio
for Gilead Sciences Inc.

Provide Cash Ratio
for Gilead Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Gilead Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Gilead Sciences Inc?

What is the current Free Cash Flow
of Gilead Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gilead Sciences Inc.

Business Breakdown

Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, an...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gilead Sciences Inc

Current Assets 13.1B
Cash & Short-Term Investments 5B
Receivables 4.6B
Other Current Assets 3.4B
Non-Current Assets 41.5B
PP&E 5.4B
Intangibles 28.9B
Other Non-Current Assets 7.2B
Current Liabilities 11.7B
Other Current Liabilities 11.7B
Non-Current Liabilities 24.4B
Other Non-Current Liabilities 24.4B
Efficiency

Earnings Waterfall
Gilead Sciences Inc

Revenue
28.3B USD
Cost of Revenue
-6.3B USD
Gross Profit
22B USD
Operating Expenses
-11.2B USD
Operating Income
10.9B USD
Other Expenses
-10.7B USD
Net Income
126m USD

Free Cash Flow Analysis
Gilead Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Gilead Sciences reported a robust third quarter in 2024, achieving total product sales of $7.5 billion, a 7% year-over-year increase, driven by growth in HIV, oncology, and liver disease. The company raised its revenue guidance for 2024, predicting total product sales between $27.8 billion and $28.1 billion. HIV sales grew 9% to $5.1 billion, surpassing previous growth expectations. Notably, lenacapavir for HIV prevention has been awarded breakthrough therapy designation and is set for regulatory filing by year-end. Livdelzi's launch exceeded expectations, and Gilead anticipates substantial momentum into 2025. Earnings per share guidance has been increased to $4.25-$4.45.

What is Earnings Call?
Fundamental Scores

GILD Profitability Score
Profitability Due Diligence

Gilead Sciences Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROE
61/100
Profitability
Score

Gilead Sciences Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

GILD Solvency Score
Solvency Due Diligence

Gilead Sciences Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Low D/E
Average Altman Z-Score
Long-Term Solvency
Short-Term Solvency
59/100
Solvency
Score

Gilead Sciences Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 97.82 USD with a low forecast of 69.69 USD and a high forecast of 131.25 USD.

Lowest
Price Target
69.69 USD
22% Downside
Average
Price Target
97.82 USD
9% Upside
Highest
Price Target
131.25 USD
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GILD?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Nov 22, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for GILD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GILD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

GILD News

Other Videos

Profile

Gilead Sciences Inc Logo
Gilead Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

111.8B USD

Dividend Yield

3.41%

Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The company sells and distributes its products in the United States through the wholesale channel. The company operates in more than 35 countries worldwide.

Contact

CALIFORNIA
Foster City
333 Lakeside Dr
+16505743000.0
www.gilead.com

IPO

1992-01-22

Employees

14 400

Officers

Chairman & CEO
Mr. Daniel P. O'Day
Chief Financial Officer
Mr. Andrew D. Dickinson
Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Ms. Deborah H. Telman
Chief Commercial Officer
Ms. Johanna Mercier
Chief Medical Officer
Dr. Merdad V. Parsey M.D., Ph.D.
Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Sandra Patterson
Show More
Vice President of Investor Relations
Ms. Jacquie Ross C.F.A.
Executive Vice President of Human Resources
Ms. Jyoti K. Mehra
Senior Vice President of Research, Innovation & Portfolio
Dr. Linda Slanec Higgins Ph.D.
Senior Vice President of Commercial Operations of Australia, Canada, Europe
Dr. Rudolf Ertl
Show Less

See Also

Discover More
What is the Intrinsic Value of one GILD stock?

The intrinsic value of one GILD stock under the Base Case scenario is 89.71 USD.

Is GILD stock undervalued or overvalued?

Compared to the current market price of 89.76 USD, Gilead Sciences Inc is Fairly Valued.

Back to Top